Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration New agreements expand and extend November 2007 antibody collaboration Collaboration goal is to advance 4 to 5 antibodies per year into clinical development Sanofi-aventis to fund up to $160M annually for Regeneron antibody
Thursday, November 12, 2009 BiopharmaWatch Research 1 min read
Key Takeaway: Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration New agreements expand and extend November 2007 antibody collaboration Collaboration goal is to advance 4 to 5 antibodies per year into clinical development Sanofi-aventis to fund up to $160M annually for Regeneron antibody
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
2.6%
average across 15 past catalysts
Lead asset
VEGF Trap-Eye
Phase 1 · Diabetic Macular Edema
Full Press Release Details
Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration New agreements expand and extend November 2007 antibody collaboration Collaboration goal is to advance 4 to 5 antibodies per year into clinical development Sanofi-aventis to fund up to $160M annually for Regeneron antibody.